Fresh analysis indicates that patients who discontinue popular weight-loss injections like semaglutide or tirzepatide may regain lost weight at a significantly accelerated pace than those who stop conventional lifestyle plans.
Published data in a leading medical journal points out that while obese individuals can lose a large proportion of their total mass while using the jabs, the weight is regained at an average rate of nearly a kilo each month upon discontinuation.
"Users buying these medications need to be informed of the danger of quick rebound weight gain when the treatment is stopped," warns lead investigator Dr. Susan Jebb.
Such speed of recovery means a return to pre-treatment mass in about 18 months.
Comparing Treatments
The analysis, which reviewed dozens of studies involving over 9,000 of participants, compared the results of GLP-1 agonists with conventional dieting.
Scientists emphasize that individuals who lose weight through lifestyle changes alone generally have a more gradual weight regain—perhaps 0.1 kg a month—once they finish.
Understanding the Quick Regain
Nutrition scientists propose the mechanism of the injections explains the accelerated weight return.
GLP-1 drugs mimic a body's own chemical called GLP-1, which controls appetite.
"Sustained high doses of GLP-1 concentrations several times higher than normal could lead to the system to produce less of its endogenous hormone, and may also reduce sensitivity to its actions," explained Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this medication means hunger is uncontrolled, making binge eating much more probable."
A Chronic Disease?
The NHS suggest the jabs for people with weight-linked health risks, alongside prescribed diet and exercise modifications.
A number of clinicians argue that, considering the high risk of weight regain, the therapy should be considered long-term.
This perspective is reinforced by drug manufacturers, who say that the results "emphasize the chronic nature of excess weight," comparing it to managing diseases like diabetes.
Patient Experiences
Users who have stopped the jabs report a sudden resurgence of hunger.
"I experienced a switch activating and you're instantly ravenous," said one woman.
This difficulty is worsened if patients have not developed permanent lifestyle or habit changes during therapy.
Growing Adoption
Recent estimates suggest that a significant number of adults in the UK have tried these injections in the past year, with desire continuing to grow.
- Use is higher among females compared to men.
- The 40s and 50s age group shows the highest usage rates.
- A large proportion obtain the drugs through private healthcare rather than public health services.
Finally, clinicians emphasize that while GLP-1 drugs are powerful tools for shedding pounds, they are not a permanent solution and lasting health benefits hinges on ongoing behavioural changes.
